

Evidence dossier - GQG Partners

GetCoattail manager profile: <https://getcoattail.com/manager/ggg-partners> | CIK 0001697233 | Rank #6 of 149 tracked managers by reported 13F value.

Background: Founded: 2016 | HQ: Fort Lauderdale, Florida, U.S. | Style: Global and emerging-markets equities, quality growth | Key person: Rajiv Jain (founder, chairman and CIO)

Background source: <https://ggg.com/insights/ggg-partners-raises-over-us5-billion-one-year-after-its-launch/>

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-12 Reported total value: \$53.8B Positions: 102 Top-10 concentration: 53.1% of reported value.

Ticker	Company	Weight	Reported value
PM	Philip Morris Intl Inc	15.29%	\$8.2B
CB	Chubb Limited	7.91%	\$4.3B
PBR	Petroleo Brasileiro S A	5.81%	\$3.1B
ENB	Enbridge Inc	4.95%	\$2.7B
XOM	Exxon Mobil Corp	4.29%	\$2.3B
MO	Altria Group Inc	3.36%	\$1.8B
CI	The Cigna Group	3.03%	\$1.6B
PGR	Progressive Corp	2.86%	\$1.5B
VZ	Verizon Communications Inc	2.83%	\$1.5B
BTI	British Amern Tob Plc	2.82%	\$1.5B

2. Hypothetical 13F-clone results

Window: 2017-02-14 to 2026-10-02 (39 filings). Cumulative: +489.3% CAGR: +20.23% SPY same window: cumulative +283.4%, CAGR +14.98%. Trailing CAGR - 10Y: n/a, 5Y: +20.60%, 3Y: +28.78%, 1Y: +9.46%. Max drawdown (month-end, approximate): -18.1%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2016Q4	0001062993-17-000926	2017-02-14	43
2017Q1	0001062993-17-002540	2017-05-15	46
2017Q2	0001062993-17-003694	2017-08-11	59
2017Q3	0001062993-17-004841	2017-11-13	56
2017Q4	0001062993-18-000715	2018-02-14	53
2018Q1	0001062993-18-002174	2018-05-14	51
2018Q2	0001062993-18-003387	2018-08-14	44

2018Q3	0001062993-18-004634	2018-11-14	48
2018Q4	0001062993-19-000963	2019-02-15	48
2019Q1	0001062993-19-002210	2019-05-14	39
2019Q2	0001062993-19-003425	2019-08-14	44
2019Q3	0001062993-19-004467	2019-11-14	43
2019Q4	0001062993-20-000780	2020-02-13	57
2020Q1	0001062993-20-002378	2020-05-14	58
2020Q2	0001062993-20-004080	2020-08-19	63
2020Q3	0001062993-20-005636	2020-11-13	67
2020Q4	0001062993-21-001371	2021-02-12	59
2021Q1	0001062993-21-004592	2021-05-14	67
2021Q2	0001062993-21-007482	2021-08-13	80
2021Q3	0001062993-21-010947	2021-11-16	84
2021Q4	0001062993-22-004303	2022-02-14	77
2022Q1	0001062993-22-012339	2022-05-13	72
2022Q2	0001062993-22-017940	2022-08-15	74
2022Q3	0001062993-22-021909	2022-11-14	83
2022Q4	0001062993-23-002839	2023-02-13	85
2023Q1	0001062993-23-010842	2023-05-12	76
2023Q2	0001062993-23-016254	2023-08-11	68
2023Q3	0001062993-23-020626	2023-11-13	73
2023Q4	0001062993-24-002850	2024-02-13	76
2024Q1	0001062993-24-010071	2024-05-13	86
2024Q2	0001062993-24-014831	2024-08-12	79
2024Q3	0001062993-24-018992	2024-11-13	78
2024Q4	0001062993-25-002114	2025-02-11	92
2025Q1	0001062993-25-009131	2025-05-13	86
2025Q2	0001062993-25-014256	2025-08-13	93
2025Q3	0001062993-25-016752	2025-11-13	93
2025Q4	0001062993-26-000911	2026-02-13	87
2026Q1	0001062993-26-002533	2026-05-12	81
2026Q2	0001062993-26-004224	2026-08-12	102

4. Coverage and adjustments

Price coverage at the latest filing: 93.7% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.